Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -51.23% and -98.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what...
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +10.70% and +150.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues...
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies...
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective,...
